Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

27 Apr 2021

Lobe Sciences Enters into Joint Venture with Virtual Psychedelics Incorporated to Develop Multi-Sensory Pods for Clinical Psychedelic Use

By Microdose

Press Releases

27 Apr 2021

Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

26 Apr 2021

Mindset Pharma Invited to Present at H.C. Wainwright “Psychedelics in Psychiatry and Beyond” Virtual Conference

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

26 Apr 2021

Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab

Clinical trial will evaluate safety and psychoactive properties of natural Psilocybin product extracted and formulated at 7,000-square-foot laboratory in British Columbia, Canada VANCOUVER, BC, April 26, 2021 /CNW/ - Numinus...

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

20 Apr 2021

Lobe Sciences Appoints Benjamin Kelmendi, MD from Yale University to Scientific Advisory Board

By Microdose

Press Releases

20 Apr 2021

Tryp Therapeutics Reports on Key Milestones for 2021

San Diego, California–(Newsfile Corp....

By Microdose

Press Releases

20 Apr 2021

Mindset Pharma Announces Strong Confirmation of In Vivo Proof-of-Concept Across Its Entire New Drug Program Portfolio

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

19 Apr 2021

Mindset Pharma Announces Exercise of Over-Allotment Option for Additional Gross Proceeds of $1.052 Million

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

15 Apr 2021

Mindset Pharma Announces Closing of $7.5 Million Bought Deal Public Offering

Toronto, Ontario–(Newsfile Corp....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.